ArticleJournal of inflammation research2026
Preoperative Systemic Pan-Immune-Inflammation Value Predicts Posthepatectomy Liver Failure After Laparoscopic Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-hepatectomy liver failure (PHLF) remains a major cause of morbidity after liver resection for hepatocellular carcinoma (HCC). Routine blood-count-based inflammatory indices may complement established liver reserve assessments. This study evaluated whether preoperative systemic pan-immune-inflammation value (S-PIV) predicts PHLF after conventional laparoscopic hepatectomy for HCC. Methods: We conducted a single-center retrospective cohort study of consecutive patients who completed conventional laparoscopic hepatectomy for liver tumors between January 2017 and December 2025. Eligible patients had pathologically confirmed HCC and complete preoperative laboratory data within 7 days before surgery. Planned open hepatectomy, conversion to open surgery, and robotic-assisted hepatectomy were outside the predefined cohort scope. S-PIV was calculated as neutrophil count × monocyte count × platelet count / lymphocyte count. The primary outcome was ISGLS-defined PHLF, analyzed as any-grade PHLF versus no PHLF. Discrimination was assessed using ROC analysis, dose-response using restricted cubic splines, and clinical utility using decision curve analysis. Results: Among 582 screened patients, 356 were included; 68 (19.1%) developed PHLF. Preoperative S-PIV showed good discrimination for PHLF (AUC 0.873). The Youden index identified an optimal cut-off of 455.4, with sensitivity 0.726 and specificity 0.908. S-PIV showed higher AUCs than NLR (0.831) and PLR (0.848). Higher S-PIV was associated with PHLF in univariable analysis (per 100 units: OR 1.12, 95% CI 1.06-1.45; P<0.001) and remained independently associated after sequential adjustment for demographics/comorbidities, liver functional reserve, and tumor/operative factors (Model 3 per 100 units: OR 1.06, 95% CI 1.03-1.13; P<0.001). Restricted cubic splines showed a graded risk increase without evidence of nonlinearity, and decision curve analysis suggested net benefit across threshold probabilities of approximately 10%-70%. Conclusion: Preoperative S-PIV, derived from routine blood counts, may serve as a practical adjunct for PHLF risk stratification after conventional laparoscopic hepatectomy for HCC. External multicenter validation and calibration are urgently required before routine implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.